COVID-19 Antibodies Are Similar for Those With Solid Tumors Compared With Those Without 6-Months After the Second Dose

Article

Patients with cancer and those without cancer had similar serologic results 6-months after receiving their second BNT162b2 vaccine.

After 6 months, patients with solid tumors and who received the second dose of Pfizer’s BNT162b2 vaccine (Comiraty) retained similar levels of SARS-CoV-2 antibodies compared with the general population of patients without cancer, according to a study published by the American Association for Cancer Research.1

In total, 79% of patients (n = 122) who were receiving active treatment for cancer were compared with 84% (n = 114) of those in the control group. There was no significant difference found between groups when comparing age, sex, or disease stage. Among the cancer cohort, treatment with chemotherapy was associated with a seronegative serologic status vs other therapies (27% vs 10%; OR, 0.31; P = .02). Among the population of patients who were seronegative, 81% were actively undergoing chemotherapy. In the population of seropositive individuals, a female predominance was noted in the control cohort compared with the patient group (93% vs 75%; OR, 0.21; P = .004).

“In our study we saw that in all outcomes, including immunogenicity, infectivity rate throughout the 6-month period, and safety, patients with solid tumors depicted a similar trend as the general population,” Irit Ben-Aharon, MD, PhD, director of the Oncology Division at Rambam Healthcare Campus in Israel, said in a press release.2

A total of 154 patients who were undergoing active intravenous treatment for their disease were included in the study, as well as the 135 age-matched health care workers who acted as the control group. The majority of patients with cancer who enrolled on the study were men (55%; n = 84) and the median patient age was 66 years. In the control group, 56% of participants were men (n = 75) and the median age was 63 years.

Patients were tested 166±29 days after the second dose and 187 days from the first dose. In the patient group, 84% (n = 129) had metastatic disease. The most common cancer types among patients who enrolled on the study included gastrointestinal cancer (36%; n = 56), lung cancer (23%; n = 36), breast cancer (17%; n = 26), and genitourinary cancer (11%; n = 18). Most patients had metastatic disease (84%; n = 129). Active cancer therapies included chemotherapy (62%), biological agents (36%), or immunotherapy (30%), although some patients notably received more than 1 class of drug.

Between the 2 cohorts, no significant difference in median absolute serology titer was noted among seropositive individuals. Additionally, both cohorts demonstrated a drastic decline over time in serology titers over 6 months, however, it remained above threshold value. A total of 15% of seropositive patients became seronegative after 6 months, which was comparable with the control group. Patients who achieved seronegativity remained seronegative throughout the study.

Investigators reported 1 documented case of COVID-19 infection following the second dose of the vaccine in the patient cohort, which required hospitalization. Of note, there were no other reported cases of COVID-19 during this study.

Elevation of liver enzyme levels was documented in 10% of patients up to 6-weeks following the first dose. Additionally, 5% of patient had newly documented regional lymphadenopathy that was identified through CT or PET scans that were performed during routine cancer care.

In total, 6% (n = 9) of patients’ anticancer treatment was delayed for 2 weeks after vaccination; all patients within this population were receiving chemotherapy. Additional treatment delays were due to neutropenia (n = 7), mild thrombocytopenia (n =1), and neutropenia with herpes labials (n = 1). In all patients with neutropenia, there was a gradual decline before vaccination, or neutropenia was found in other cycles. All patients had treatment renewed within a week for all patients.

References

1. Waldhorn I, Holland R, Goshen-Lago T, et al. Six month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. Published online first, September 2, 2021. doi: 10.1158/2159-8290.CD-21-1072

2. Six-month efficacy of Pfizer/BioNTech COVID-19 vaccine in patients with solid tumors similar to general population. News Release. American Society for Cancer Research. September 2, 2021. Accessed September 2, 2021.

Related Videos
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Related Content